Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of AZD0186 in Healthy Volunteers
NCT05694741Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Dec 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD0186 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by AstraZeneca. Primary endpoints: Adverse Events up to 6 weeks and Serious Adverse Events up to 6 weeks. Started Dec 2022; status: terminated.
02
Drugs
AZD0186
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05694741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05694741.